The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.
 
Sarina Anne Piha-Paul
No Relationships to Disclose
 
Cinta Hierro
No Relationships to Disclose
 
Valentina Boni
No Relationships to Disclose
 
Victor Moreno
No Relationships to Disclose
 
Noah M. Hahn
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Health Advances; Inovio Pharmaceuticals; Merck; Oncogenex; Pieris Pharmaceuticals
Research Funding - Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Heat Biologics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Principa Biopharma (Inst)
 
Rhonda L. Bitting
No Relationships to Disclose
 
Todd Michael Bauer
Employment - Sarah Cannon Research Institute; Tennessee Oncology
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunogen (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Principa Biopharma (Inst); Stemline Therapeutics (Inst)
 
Rahul Raj Aggarwal
No Relationships to Disclose
 
Steven Gourlay
No Relationships to Disclose
 
Patrick Smith
No Relationships to Disclose
 
Eleni Venetsanakos
No Relationships to Disclose
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Clearlight Diagnostics; Genentech; Inflection Biosciences; Novartis; Pieris Pharmaceuticals; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; Effective Pharmaceuticals; Genentech; Jounce Therapeutics; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem; Zymeworks
 
Ken Brameld
No Relationships to Disclose
 
Dane Karr
No Relationships to Disclose
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Celgene; Chugai Pharma; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche; Sanofi; Symphony Evolution; Taiho Pharmaceutical; Takeda